HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
HTG Molecular Diagnostics Inc. (HTGMQ) - Total Assets
Latest total assets as of March 2023: $10.87 Million USD
Based on the latest financial reports, HTG Molecular Diagnostics Inc. (HTGMQ) holds total assets worth $10.87 Million USD as of March 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HTG Molecular Diagnostics Inc. - Total Assets Trend (2012–2022)
This chart illustrates how HTG Molecular Diagnostics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HTG Molecular Diagnostics Inc. - Asset Composition Analysis
Current Asset Composition (December 2022)
HTG Molecular Diagnostics Inc.'s total assets of $10.87 Million consist of 88.0% current assets and 12.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.7% |
| Accounts Receivable | $1.42 Million | 8.0% |
| Inventory | $909.33K | 5.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2022)
This chart illustrates how HTG Molecular Diagnostics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HTG Molecular Diagnostics Inc.'s current assets represent 88.0% of total assets in 2022, a decrease from 92.8% in 2012.
- Cash Position: Cash and equivalents constituted 68.7% of total assets in 2022, down from 86.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 8.0% of total assets.
HTG Molecular Diagnostics Inc. Competitors by Total Assets
Key competitors of HTG Molecular Diagnostics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
HTG Molecular Diagnostics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - HTG Molecular Diagnostics Inc. generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - HTG Molecular Diagnostics Inc. is currently not profitable relative to its asset base.
HTG Molecular Diagnostics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 2.99 | 9.49 |
| Quick Ratio | 1.30 | 2.75 | 9.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.63 Million | $ 16.92 Million | $ 41.20 Million |
HTG Molecular Diagnostics Inc. - Advanced Valuation Insights
This section examines the relationship between HTG Molecular Diagnostics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -41.6% |
| Total Assets | $17.78 Million |
| Market Capitalization | $221.00 USD |
Valuation Analysis
Below Book Valuation: The market values HTG Molecular Diagnostics Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HTG Molecular Diagnostics Inc.'s assets decreased by 41.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HTG Molecular Diagnostics Inc. (2012–2022)
The table below shows the annual total assets of HTG Molecular Diagnostics Inc. from 2012 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $17.78 Million | -41.64% |
| 2021-12-31 | $30.46 Million | -13.46% |
| 2020-12-31 | $35.20 Million | -21.99% |
| 2019-12-31 | $45.12 Million | +3.08% |
| 2018-12-31 | $43.77 Million | +105.92% |
| 2017-12-31 | $21.26 Million | +15.18% |
| 2016-12-31 | $18.45 Million | -53.16% |
| 2015-12-31 | $39.39 Million | +351.34% |
| 2014-12-31 | $8.73 Million | +98.47% |
| 2013-12-31 | $4.40 Million | -47.85% |
| 2012-12-31 | $8.43 Million | -- |